Laudenschlager Mark D, Geis Michael C
Sanford School of Medicine, The University of South Dakota, Pathology Residency Program, USA.
S D Med. 2010 Sep;63(9):311-3, 315.
We describe a 42-year-old male who was in good health until he presented with a high grade B-cell non-Hodgkin lymphoma/leukemia that had both MYC and t(14;18) translocations. This process has now been classified as "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma," according to the 2008 World Health Organization Classification of Tumours of Haematopoitic and Lymphoid Tissues. The clinical presentation, pathologic work-up including examination of the peripheral blood, lymph node biopsy, bone marrow aspiration and biopsy are included. Treatment consisted of seven cycles of chemotherapy following the CALGB protocol 9251. Prognosis is generally reported as poor in these aggressive "double-hit" lymphomas. However, this patient's disease has now been in remission for two years.
我们描述了一名42岁男性，他此前身体健康，后来出现了一种同时具有MYC和t(14;18)易位的高级别B细胞非霍奇金淋巴瘤/白血病。根据2008年世界卫生组织造血与淋巴组织肿瘤分类，这一过程目前被归类为“无法分类的B细胞淋巴瘤，具有介于弥漫性大B细胞淋巴瘤和伯基特淋巴瘤之间的特征”。文中包括了临床表现、病理检查（包括外周血检查、淋巴结活检、骨髓穿刺和活检）。治疗采用了遵循CALGB方案9251的七个周期化疗。一般报道称，这些侵袭性“双打击”淋巴瘤的预后较差。然而，该患者的疾病目前已缓解两年。
